|Home||» Products||» Daclatasvir||» Mydacla|
- Formulations Type
- General Drugs
- Formulations Form
- Treatments & Functions
- Treating of hepatitis C
- Gender/Age Group
The mydacla that we are offering is proven to effectively treat hepatitis C of genotype 3. It obstructs the HCV nonstructural macromolecules NS5A. Contemporary study indicates that it aims two methods of infection reproduction mechanism, allowing quick minimization of HCV RNA. Our medicine has be checked in amalgamation regimes with ribavirin of pegylated interferonand and with various straight working antiviral enzymes comprising sofosbuvir and asunaprevir.
If you have any doubt regarding our medicine, kindly visit your nearest clinic or your doctor.
Our medicine is supposed to be exercised only when it is prescribed by the doctor. It is highly recommended to not to share this drug among people.
If your signs do not get better or get worse, pay visit to the doctor immediately.
Consult your doctor to know how to discard the unused drug.
The information that is provided above is only a summary. It do not include all information about the medicine. If you queries about the drug that you are one or would like to know more, consult your pharmacist or healthcare provider.
Disclaimers: The summary shall not be utilized to determine whether or not to consume the medicine or any other related medicine. Only your doctor possess the information to determine, which drugs are accurate and useful for you. Thus, this data does not support any drug as risk less, effectual, or authorized for curing any health condition or patient.
MYDACLA 60 MG
Mydacla description are mentioned below:
- Payment Terms
- Telegraphic Transfer (T/T), Others
- Delivery Time
- 7-14 Days
- Main Export Market(s)
- Asia, Australia, Central America, North America, South America, Eastern Europe, Western Europe, Middle East, Africa
- Main Domestic Market
- All India